Almirall Expands Dermatology Portfolio with New EADV 2026 Data…

Event summary

Almirall presented over 20 abstracts at EADV 2026, focusing on atopic dermatitis, psoriasis, and actinic keratosis.
New data on lebrikizumab and tildrakizumab demonstrated positive treatment outcomes across diverse patient populations.
Late-breaking results from the ADlong study showed sustained efficacy of lebrikizumab over five years.
Almirall highlighted the effectiveness of tirbanibulin and CAL/BDP PAD cream in real-world settings.
The company hosted educational symposia and an interactive industry hub to discuss clinical relevance.

The big picture

Almirall's presentation at EADV 2026 underscores its commitment to advancing dermatology treatments. The company's focus on generating robust clinical and real-world evidence aligns with the growing demand for effective, long-term solutions in medical dermatology. With a pipeline dedicated solely to this field, Almirall aims to address high unmet needs and differentiate itself in a competitive market.

What we're watching

Clinical Validation: How the sustained efficacy data for lebrikizumab will impact its market positioning.
Market Expansion: Whether Almirall can leverage the new data to expand its dermatology portfolio globally.
Competitive Dynamics: The pace at which competitors will respond with their own clinical evidence in dermatology.